Biotech & Health Tech
STAT+: Dutch antitrust regulators probe Biogen over test for its MS drug
Dutch anti-trust regulators are investigating allegations that Biogen may have abused its dominant position in the market for MS treatments and associated blood tests.
Dutch anti-trust regulators are investigating allegations that Biogen may have abused its dominant position in the market for MS treatments and associated blood tests.
This is a summary of the story. Read the full article at Stat News (Biotech & Health Tech) ↗